AJTMH ASTMH Job Mart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 58(5), 1998, pp. 619-624
Copyright © 1998 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lell, B
Right arrow Articles by Kremsner, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lell, B
Right arrow Articles by Kremsner, P.
Related Collections
Right arrow Malaria
Right arrow Plasmodium
American Journal of Tropical Medicine and Hygiene, Vol 58, Issue 5, 619-624
Copyright © 1998 by American Society of Tropical Medicine and Hygiene

Research Articles


Malaria chemotherapy trial at a minimal effective dose of mefloquine/sulfadoxine/pyrimethamine compared with equivalent doses of sulfadoxine/pyrimethamine or mefloquine alone

B Lell, LG Lehman, Schmidt-Ott JR, D Sturchler, J Handschin, and PG Kremsner

In murine malaria the addition of mefloquine to sulfadoxine/pyrimethamine has been shown to exert an additive effect and to significantly slow the emergence of resistance to the individual components. In a pilot study carried out in Gabon, a reduced dosage of the triple combination with a mean of 1 mg/kg of mefloquine/2 mg/kg of sulfadoxine/0.1 mg/kg of pyrimethamine (Fansimef; Roche, Basel, Switzerland) had previously been shown to achieve high cure rates in Plasmodium falciparum malaria. To evaluate the additive effect, a randomized, double-blind trial in school children with mild P. falciparum malaria was performed in Gabon. Two hundred thirty-one patients evaluated received a single dose of either the triple combination with a mean of 1.07 mg/kg of mefloquine/2.14 mg/kg of sulfadoxine/0.11 mg/kg of pyrimethamine (group MSP), or 1.07 mg/kg of mefloquine alone (group M), or 2.14 mg/kg of sulfadoxine/0.11 mg/kg of pyrimethamine alone (group SP). In the MSP group and the SP group, 67% and 69% of the patients were parasitologically cured, respectively, compared with only 13% in the M group (P < 0.001). A significantly higher parasitemia was found in the M group compared with the MSP group or the SP group on days 2 and 3 after the start of treatment. The high efficacy of the low dose sulfadoxine/pyrimethamine regimen was the most surprising finding of this study.


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
S. Oyakhirome, S. Issifou, P. Pongratz, F. Barondi, M. Ramharter, J. F. Kun, M. A. Missinou, B. Lell, and P. G. Kremsner
Randomized Controlled Trial of Fosmidomycin-Clindamycin versus Sulfadoxine-Pyrimethamine in the Treatment of Plasmodium falciparum Malaria
Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1869 - 1871.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. P. Mawili-Mboumba, J. F. J. Kun, B. Lell, P. G. Kremsner, and F. Ntoumi
Pfmdr1 Alleles and Response to Ultralow-Dose Mefloquine Treatment in Gabonese Patients
Antimicrob. Agents Chemother., January 1, 2002; 46(1): 166 - 170.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. F. J. Kun, L. G. Lehman, B. Lell, R. Schmidt-Ott, and P. G. Kremsner
Low-Dose Treatment with Sulfadoxine-Pyrimethamine Combinations Selects for Drug-Resistant Plasmodium falciparum Strains
Antimicrob. Agents Chemother., September 1, 1999; 43(9): 2205 - 2208.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Society of Tropical Medicine and Hygiene.